{"id":"NCT04372186","sponsor":"Genentech, Inc.","briefTitle":"A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-05-14","primaryCompletion":"2020-08-18","completion":"2020-09-22","firstPosted":"2020-05-01","resultsPosted":"2021-09-27","lastUpdate":"2023-02-10"},"enrollment":377,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19 Pneumonia"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Tocilizumab","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Tocilizumab","type":"EXPERIMENTAL"}],"summary":"This study (EMPACTA) will a) evaluate the efficacy and safety of tocilizumab (TCZ) compared with a placebo in combination with standard of care (SOC) in hospitalized participants with COVID-19 pneumonia, and b) include an optional long-term extension for eligible participants to explore the long-term sequelae of resolved COVID-19 pneumonia.","primaryOutcome":{"measure":"Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28","timeFrame":"Up to Day 28","effectByArm":[{"arm":"Tocilizumab","deltaMin":12.04,"sd":null},{"arm":"Placebo","deltaMin":19.26,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":44,"countries":["United States","Brazil","Kenya","Mexico","Peru","South Africa"]},"refs":{"pmids":["33332779","33201228"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":250},"commonTop":["Constipation","Anxiety"]}}